AFFILIATIONS
1 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
2 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
3 Department of Hematology, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, Chengdu, China
4 Department of Hematology, Hongqiao International Institute of Medicine, Shanghai Institute of Hematology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
5 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
6 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
7 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
8 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
9 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
10 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
11 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
12 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
13 Department of Hematology, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, Chengdu, China
14 Department of Hematology, Hongqiao International Institute of Medicine, Shanghai Institute of Hematology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
15 Department of Hematology, Hongqiao International Institute of Medicine, Shanghai Institute of Hematology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
16 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
17 Department of Hematology, Hongqiao International Institute of Medicine, Shanghai Institute of Hematology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
18 Department of Hematology, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, Chengdu, China
19 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
20 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China, Wuxi Branch, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicin, Wuxi, Jiangsu, China
ABSTRACT
Introduction
Intensive chemotherapy with anthracycline plus cytarabine (7+3) remains standard induction for fit patients with AML, but remission rates remain suboptimal, particularly in ELN 2022 intermediate- or adverse-risk disease. In addition to morphologic remission, measurable residual disease (MRD) negativity is associated with improved long-term outcomes. Sonrotoclax, a potent and selective next-generation BCL-2 inhibitor, may enhance the efficacy of intensive chemotherapy without substantially increasing toxicity. We evaluated sonrotoclax plus chemotherapy as induction therapy in newly diagnosed fit AML, with consolidation guided by baseline ELN risk and post-induction MRD status.
Methods
In this single-arm phase 2 study, patients aged 18-75 years with newly diagnosed AML were enrolled. The first 6 patients entered a safety run-in phase to determine the target dose of sonrotoclax. In the treatment phase, patients received sonrotoclax on days 5-14 at the dose determined in the safety run-in phase plus 7+3 as induction therapy for up to 2 cycles (28-day cycle). Patients achieving composite CR (CRc: CR, CRh, or CRi) received consolidation according to ELN 2022 risk stratification and post-induction MRD status. Patients with favorable-risk disease and MRD negativity received intermediate- or high-dose cytarabine (IDAC or HiDAC) or 7+3, whereas patients with favorable-risk disease and MRD positivity or intermediate-/adverse-risk disease received sonrotoclax on days 1-7 plus IDAC on days 1-3. Allogeneic stem-cell transplantation (ASCT) was allowed at investigator discretion for intermediate-/adverse-risk patients. Maintenance therapy consisted of sonrotoclax plus azacitidine alternating with azacitidine monotherapy every 2 cycles for up to 12 months. The primary endpoint was 2-year EFS. Secondary endpoints included CRc rate after induction, MRD negativity (MRD <0.1% by multiparameter flow cytometry) rate among CRc patients, and safety.
Results
Between Oct 22, 2024 and Mar 18, 2026, 48 patients were enrolled; median age was 43.5 years (range, 20-72), and 43.8% were male. ELN risk was favorable in 21 (43.8%), intermediate in 13 (27.1%), and adverse in 14 (29.2%) patients. Seven patients had FLT3-ITD/TKD mutations and 13 had RAS pathway mutations. Among adverse-risk patients, 9 had AML-MR, including 2 with prior MDS and 2 with complex karyotype.
No DLTs occurred in the safety run-in phase, and sonrotoclax 160 mg was the target dose in treatment phase. As of Jun 9, 2026, with a median follow-up of 7.3 months (range, 2.4-18.4), 47 patients had completed induction. One adverse-risk patient achieved PR after the first induction cycle and remained on the second cycle. Thirty-four patients proceeded to consolidation, and 12 entered maintenance.
Among 48 efficacy-evaluable patients, the CRc rate after induction was 89.6% (43/48), including CR in 87.5% and CRh in 2.1%. Of 43 responders, 42 achieved CRc after 1 induction cycle and 1 after 2 cycles. By ELN risk, CRc was 100% in favorable-/intermediate-risk patients and 64.3% in adverse-risk patients. MRD negativity among CRc patients was 90.7% (39/43): 95.2% (20/21), 92.3% (12/13), and 77.8% (7/9) in favorable-, intermediate-, and adverse-risk groups, respectively. All 6 patients with FLT3-ITD mutation achieved MRD-negative CR, and 11/13 (84.6%) with RAS pathway mutation achieved CRc. Among 4 patients with persistent MRD after induction, 3 received sonrotoclax plus IDAC and 1 proceeded directly to allo-SCT; all subsequently achieved MRD negativity.
Grade ≥3 TEAEs were mainly hematologic, including leukopenia (97.9%), thrombocytopenia (91.7%), neutropenia (93.8%), and anemia (81.3%). In responders, median hematologic recovery (ANC ≥1000/μL and PLT ≥100000/μL) was 26 days, consistent with prior reports for 7+3 alone. Grade ≥3 infections occurred in 6.3%. SAE occurred in 10.4% of patients. No tumor lysis syndrome was observed. TEAEs leading to dose reduction, dose interruption, and treatment discontinuation occurred in 4.2%, 18.8%, and 6.3% of patients, respectively. No TEAE led to death.
Conclusions
Sonrotoclax plus intensive chemotherapy was highly active in newly diagnosed fit AML, achieving 89.6% CRc and 90.7% MRD negativity overall and across ELN risk groups; MRD negativity exceeded that in our prior intensive chemotherapy study (62.0%) (Zhang et al. Am J Hematol 2022). MRD-guided therapy further deepened remission after induction. Tolerability was favorable.